XENE - Neurocrine reports Phase 2 study failures for two drug candidates
2023-11-09 16:56:54 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
- Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
- Neurocrine Biosciences Q3 2023 Earnings Preview
- Neurocrine says new Ingrezza version is under FDA review
For further details see:
Neurocrine reports Phase 2 study failures for two drug candidates